Harnessing AI to Decode Untapped Diverse Chemistry to Develop Breakthrough Medicines for Chronic Disease.
About Montai
Montai is a different kind of drug company, purpose-built to make big leaps forward in the predictable discovery of great drugs for chronic diseases.
Montai is pioneering at the intersection of machine learning, biology, and diverse untapped chemistry that is rich with potential solutions to disease — Anthromolecule™ compounds. Tested and refined through eons of human co-evolution through chronic consumption, the topologically rich structures across Anthromolecules offer opportunities to engage complex biological targets with precision and selectivity, making this diverse chemistry a privileged starting point for small molecule drugs.
Using leading edge AI and end to end automation, Montai finds, prioritizes and optimizes promising drug leads in this vast and untapped chemical space. The result: small molecule drug discovery that is more predictable and productive than ever before for the most complex biology.
Our Mission
Our understanding of human biology has grown exponentially, offering new insights into disease and ways to intervene. Yet many of today's innovative therapies remain out of reach or insufficient for most patients. What's more, finding new oral medicines has historically been largely a trial-and-error endeavor with many of the most important validated biological pathways considered undruggable with small molecules. Montai aims to change this.
-
6 in 10
US adults living with chronic disease -
>50%
Most severe patients
are untreated -
<10%
Proportion of innovative medicines taken that are small molecules -
7%
Likelihood of approval for novel small molecules
Our Approach
Predictable and Highly Productive Drug Discovery
Drug discovery began as a serendipitous, trial-and-error effort. Montai is pioneering a new era of predictable discovery for small molecule medicines that would not have been possible even a few years ago. Fueled by the exponential growth in biochemical data and far more powerful computational tools, we are decoding the complex language of chemistry computationally, generating deep network understanding of chemical structure to biological function relationships, so that we find the right molecules and can efficiently predict the potential in any molecule across the widest possible chemical diversity to become a drug.
When we apply these powerful tools to aggregate and then survey the landscape of richly diverse Anthromolecule chemistry, we can predictably and efficiently find, prioritize and validate the best possible keys to unlock any biology pathway door.
Diverse, Untapped Chemistry at Unprecedented Scale
Montai is aggregating and curating the world's largest, fully-annotated set of Anthromolecule chemistry - bioactive molecules humans have chronically consumed in foods, supplements, and herbal medicines.
We have developed proprietary tools to generate and curate over 1 billion analogs derived from Anthromolecule chemistry which opens accessibility to this privileged diverse chemistry at scale for efficient drug development. Analogs are accessible in few retrosynthetic steps and have good drug like properties.
Embedded in this space are many proven molecular modalities for unlocking complex biology, such as covalent binders, macrocycles, molecular glues and protein-protein interaction inhibitors. Now we can search this space universally for the first time to find optimal solutions.
Precision Matched to Biology
Anthromolecules have co-evolved in humans over millennia, interacting with our own biology to maintain health. Approximately 87% of Anthromolecules are structurally unique versus synthetic libraries most drug development focuses on today, presenting a far greater variety of building blocks for engaging disease pathways that have eluded traditional medicinal chemistry approaches. Montai's AI tools efficiently unlock precision connections between this diverse chemistry and the known drivers of complex disease biology creating new ways to treat diseases with a pill.
The CONECTA Platform
The CONECTA™ platform is a new drug operating system enabling the predictable discovery of transformative small molecule drugs from diverse untapped human chemistry.
Unlike other small molecule AI approaches that focus on physical binding to a specific target, Montai's CONECTA platform starts with validated pathways and matches optimal chemistry to biology for superior outcomes and optionality.
These bioactive nominations are then filtered for drug-like properties and ranked with CONECTA's proprietary ML tools, allowing scientists to select and focus optimization efforts on the most promising leads.
CONECTA supercharges drug discovery and development with incredible efficiency, insights, and capabilities by enabling far more and earlier integrative decision making across multiple differentiated candidates as well as discovering multiple uncorrelated candidates which de-risks development and provides unprecedented optionality.
AnthroGraph
Bioactivity Atlas
Pathway Solutions
The CONECTA™ pipeline
-
1B+
Over 1 Billion Anthrolog™ Molecules -
9 / 7
9 Programs Across 7 IAI Targets -
1000x
Up to 1000x efficiency in finding high potential keys for complex targets
While the CONECTA™ platform has demonstrated it's potential across over 80 mechanisms of action in 5 therapeutic areas, our advancing pipeline is focused on biologic replacements and historically difficult to drug transcription factors in inflammation and autoimmune diseases given large unmet patient needs across all major IAI diseases for efficacious, accessible therapies that are safe for long-term use.
Inflammation-related pathways also offer important biological network links to other chronic diseases in oncology, neurology and metabolism,. We are advancing candidates for several of these areas in addition to our focus on inflammation and autoimmune in partnership with leading pharma companies.
We envision a world where, instead of regular and costly infusions, a convenient and safe pill for long-term use effectively treats a chronic disease, where solutions exist for diseases that today have none.
Featured News
-
Montai Therapeutics Appoints Allison Bogosian, JD, as Chief People and Administrative Officer
-
Spotlight: Montai Builds a Multimodal AI Platform for Drug Discovery Using NVIDIA NIM Microservices
-
Montai Therapeutics Appoints Renowned Chemical Innovator Larry Hamann to Company's Board of Directors, Convenes Multidisciplinary Scientific Advisory Board to Inform Strategic Momentum
-
How 3 Mass. companies are using AI to design drugs
-
Breaking Boundaries in Chemical Combinatorics Machine Learning: Unveiling the ComboPath Model at NeurIPS 2023
-
Montai Health Appoints Christian Antoni, M.D., Ph.D., as Company's First Chief Medical Officer
-
Montai Health Adds Industry Leaders to its Board of Directors
-
Flagship Pioneering Unveils Montai Health to Treat and Preempt Chronic Disease Afflicting Two Billion People Worldwide
Join Us
Contact Us
-
Partnerships
We welcome the opportunity to partner with experts across areas who share our passion for creating Anthromolecule™ medicines and want to collaborate to accelerate the development of safe, efficacious and accessible therapies across diseases.
partnerships@montai.com -
Press
For media inquiries or the latest on research, thought leadership, company news, and events contact:
press@montai.com